Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cosciens Biopharma Inc (CSCI)

Cosciens Biopharma Inc (CSCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“ COSCIENS ” or the “ Company ”), a life sciences company focused on pharmaceutical therapies,...

CSCI.TO : 3.04 (+0.33%)
CSCIF : 2.1500 (-0.46%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Inc. Announces Leadership Change

TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and...

CSCI.TO : 3.04 (+0.33%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS voluntarily delists from Nasdaq, while retaining the Company’s listing on the TSX COSCIENS restructuring results in significantly lower cash outflow with operating expenses down 59% vs....

CSCI.TO : 3.04 (+0.33%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq , while retaining the Company’s listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS...

CSCI.TO : 3.04 (+0.33%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

CSCI.TO : 3.04 (+0.33%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

CSCI.TO : 3.04 (+0.33%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

CSCI.TO : 3.04 (+0.33%)
CSCI : 2.72 (-11.69%)
Goodwood to Nominate New Directors for COSCIENS Biopharma Inc.

/CNW/ - Goodwood Fund and Puccetti Funds Management Inc. (collectively, "Goodwood") announced today that Goodwood has notified COSCIENS Biopharma Inc. (NASDAQ:...

CSCI.TO : 3.04 (+0.33%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

CSCI.TO : 3.04 (+0.33%)
CSCI : 2.72 (-11.69%)
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

CSCI.TO : 3.04 (+0.33%)
CSCI : 2.72 (-11.69%)

Barchart Exclusives

1 Top Penny Stock to Watch Now
This small-cap biotech is chasing a big breakthrough in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar